Autophagy inhibition enhanced the sensitivity of non-small cell lung cancer cells to osimertinib by decreasing the expression of SRY-box transcription factor 2 (SOX2), a marker of stemness [106]. This evidence concerns the gene SOX2 and non-small cell lung carcinoma.